evidence across a significant variety of studies to indicate that fQRS is a predictor of future major adverse cardiac events (MACE) (including arrhythmic events)/mortality/poor prognosis in patients with known coronary artery disease (CAD)/ acute coronary syndromes, left ventricular dysfunction, cardiomyopathy, and Brugada syndrome. There is less evidence (but some) of this in suspected CAD, acquired QT prolongation, sarcoidosis, amyloidosis and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).
patients, overwhelming majority of these in the inferior territory. fQRS was not associated with increased mortality in those without known cardiac disease. Terho et al (2014).
NSTEMI were higher than that of ischaemic T waves at identifying culprit lesion territory. fQRS 48hrs post-PPCI was a significant predictor of MACE at 6months. Lack of expected mortality benefit of reperfusion therapy in STEMI patients who present with fQRS. Unfortunately all 3 of these were small-cohort/single-centre studies. Guo et al (2011). Ari et al (2011). Stavileci et al (2014).
and can (should?) be considered a factor in risk stratification. fQRS alone doesn’t tell us a great deal. We must still utilise good clinical judgement and the testing modalities already available to us. However if you see a fQRS, its reasonable to be suspicious! (THE IMPORTANT BIT)..
simonmark
szymonslowik
csswizardry
tmiket
marktimemedia
skipperchong
marcduiker
cassininazir
quramy
katiecoart
axbom
ianozsvald
charlesmeaden
